STOP-HF Trial: Higher Endogenous BNP and Cardiovascular Protection in Subjects at Risk for Heart Failure

B-type natriuretic peptide (BNP) possesses blood-pressure–lowering, antifibrotic, and aldosterone-suppressing properties. In Stage A and B heart failure, the carriers of the minor C allele of the BNP genetic variant rs198389 have higher circulating levels of BNP and are at decreased risk of hyperten...

Descripción completa

Detalles Bibliográficos
Autores principales: Cannone, Valentina, Ledwidge, Mark, Watson, Chris, McKie, Paul M., Burnett, John C., McDonald, Kenneth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246026/
https://www.ncbi.nlm.nih.gov/pubmed/34222720
http://dx.doi.org/10.1016/j.jacbts.2021.05.001
_version_ 1783716227837853696
author Cannone, Valentina
Ledwidge, Mark
Watson, Chris
McKie, Paul M.
Burnett, John C.
McDonald, Kenneth
author_facet Cannone, Valentina
Ledwidge, Mark
Watson, Chris
McKie, Paul M.
Burnett, John C.
McDonald, Kenneth
author_sort Cannone, Valentina
collection PubMed
description B-type natriuretic peptide (BNP) possesses blood-pressure–lowering, antifibrotic, and aldosterone-suppressing properties. In Stage A and B heart failure, the carriers of the minor C allele of the BNP genetic variant rs198389 have higher circulating levels of BNP and are at decreased risk of hypertension, new-onset left ventricular systolic dysfunction, and hospitalization for major adverse cardiovascular events. Future studies are warranted to investigate the role of BNP genetic testing and BNP-based therapy in the prevention of heart failure.
format Online
Article
Text
id pubmed-8246026
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-82460262021-07-02 STOP-HF Trial: Higher Endogenous BNP and Cardiovascular Protection in Subjects at Risk for Heart Failure Cannone, Valentina Ledwidge, Mark Watson, Chris McKie, Paul M. Burnett, John C. McDonald, Kenneth JACC Basic Transl Sci Clinical Research B-type natriuretic peptide (BNP) possesses blood-pressure–lowering, antifibrotic, and aldosterone-suppressing properties. In Stage A and B heart failure, the carriers of the minor C allele of the BNP genetic variant rs198389 have higher circulating levels of BNP and are at decreased risk of hypertension, new-onset left ventricular systolic dysfunction, and hospitalization for major adverse cardiovascular events. Future studies are warranted to investigate the role of BNP genetic testing and BNP-based therapy in the prevention of heart failure. Elsevier 2021-06-16 /pmc/articles/PMC8246026/ /pubmed/34222720 http://dx.doi.org/10.1016/j.jacbts.2021.05.001 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Clinical Research
Cannone, Valentina
Ledwidge, Mark
Watson, Chris
McKie, Paul M.
Burnett, John C.
McDonald, Kenneth
STOP-HF Trial: Higher Endogenous BNP and Cardiovascular Protection in Subjects at Risk for Heart Failure
title STOP-HF Trial: Higher Endogenous BNP and Cardiovascular Protection in Subjects at Risk for Heart Failure
title_full STOP-HF Trial: Higher Endogenous BNP and Cardiovascular Protection in Subjects at Risk for Heart Failure
title_fullStr STOP-HF Trial: Higher Endogenous BNP and Cardiovascular Protection in Subjects at Risk for Heart Failure
title_full_unstemmed STOP-HF Trial: Higher Endogenous BNP and Cardiovascular Protection in Subjects at Risk for Heart Failure
title_short STOP-HF Trial: Higher Endogenous BNP and Cardiovascular Protection in Subjects at Risk for Heart Failure
title_sort stop-hf trial: higher endogenous bnp and cardiovascular protection in subjects at risk for heart failure
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246026/
https://www.ncbi.nlm.nih.gov/pubmed/34222720
http://dx.doi.org/10.1016/j.jacbts.2021.05.001
work_keys_str_mv AT cannonevalentina stophftrialhigherendogenousbnpandcardiovascularprotectioninsubjectsatriskforheartfailure
AT ledwidgemark stophftrialhigherendogenousbnpandcardiovascularprotectioninsubjectsatriskforheartfailure
AT watsonchris stophftrialhigherendogenousbnpandcardiovascularprotectioninsubjectsatriskforheartfailure
AT mckiepaulm stophftrialhigherendogenousbnpandcardiovascularprotectioninsubjectsatriskforheartfailure
AT burnettjohnc stophftrialhigherendogenousbnpandcardiovascularprotectioninsubjectsatriskforheartfailure
AT mcdonaldkenneth stophftrialhigherendogenousbnpandcardiovascularprotectioninsubjectsatriskforheartfailure

Ejemplares similares